Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Long-term Diabetes Complications and Intensive Treatment Effects

Compared with routine care, early intensive multifactorial therapy shows little effect.... 

Advertisement

In an effort to determine the benefit of multifactorial treatment on microvascular complications among people with type 2 diabetes, Annelli Sandbaek, MD, PhD, and colleagues conducted a multicenter cluster randomized controlled trial at four centers in Denmark, the UK, and The Netherlands. Out of 3,057 people with diabetes detected by a screening process, only 2,861 were eligible for follow-ups. They were assigned to either the intensive treatment or routine care group.

The results from the four centers were collected using a fixed-effects meta-analysis. Of the patients who received intensive treatment, 22.7% showed any type of albuminuria, and patients who underwent routine care had 24.4%. Retinopathy was observed in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients. When it came to neuropathy, 4.9% was seen in intensive treatment patients, and 5.9% in routine care patients. However, in both groups the estimated glomerular filtration rate increased between baseline and follow-up; 4.31 mL/min was seen in the intensive treatment and 6.44 mL/min in the routine care groups.

According to the results of this study, researchers stated, "Compared with routine care, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was not associated with significant reductions in the frequency of microvascular events at five years."

Practice Pearls:
  • Albuminuria was 22.7% in the intensive group compared to 24% in the routine care group.
  • Retinopathy was present in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients
  • Neuropathy, 4.9%, was seen in intensive treatment patients, and 5.9% in routine care

Sandbaek A et al. Diabetes Care. 2014; doi: 10.2337/dc13-1544 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Past five issues: Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 | Diabetes Clinical Mastery Series Issue 223 | Issue 763 |

2014 Most Popular Articles:

ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
Why a Low-Carb Diet Should Be the First Approach in Diabetes Treatment
Posted December 18, 2014
Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014
Advancement in the Artificial Pancreas
Posted December 26, 2014
FDA Approves Weight-management Drug Saxenda
Posted December 26, 2014
Type 2 Diabetes Risk Lower for Blood Type O
Posted December 26, 2014
Early Insulin Therapy Makes an Impact
Posted December 26, 2014
Increased Mortality with Combining Sulfonylurea and Insulin
Posted December 26, 2014
Another SGLT2 Shows Positive Results
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are you comfortable recommending one of the 4 new FDA-approved weight loss drugs?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control